Plasma methylphenidate levels in youths with attention deficit hyperactivity disorder treated with OROS formulation

Basit Öğe Kaydı
dc.authorid0000-0002-0021-8400en_US
dc.contributor.authorYorbik O.
dc.contributor.authorMutlu C.
dc.contributor.authorOzilhan S.
dc.contributor.authorEryilmaz G.
dc.contributor.authorIsiten N.
dc.contributor.authorAlparslan S.
dc.contributor.authorSaglam E.
dc.date.accessioned2024-07-12T21:53:29Z
dc.date.available2024-07-12T21:53:29Z
dc.date.issued2015en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractBackground: There are limited studies investigating the relationship between oral release osmotic system-methylphenidate (OROS-MPH) doses and plasma methylphenidate (MPH) concentrations in children and adolescents. The aim of this study was to investigate the relationship between the doses of OROS-MPH and the plasma levels of the drug. We also examined the effects of the other drugs including aripiprazole, risperidone, fluoxetine, and sertraline on the levels of the MPH in the plasma. Methods: The files of 100 attention deficit hyperactivity disorder (ADHD) subjects (76 male, 24 female) who were diagnosed as ADHD according to the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition criteria, were screened. The ages of subjects were between 6 and 18 years (mean 11.5 ± 3.8 years). Plasma MPH levels were determined by high-performance liquid chromatography-tandem mass spectrometry assay. Results: Daily mean OROS-MPH dose used in ADHD children was 0.7 ± 0.2 mg/kg (range: 0.3-1.3 mg/kg). The mean plasma OROS-MPH was 11.6 ± 7.3 ng/mL (range: 0.5-43.4 ng/mL). There was no group difference in the mean plasma MPH and dose-related MPH levels between the groups that used any additional drug including aripiprazole (n 25), risperidone (n 10), fluoxetine (n 16), sertraline (n 10), and did not use these drugs (P > 0.05). There was a positive correlation between the OROS-MPH doses (mg/kg) and the blood MPH levels (Pearson correlation 0.40; P < 0.001). The plasma levels of MPH were found to be less than 13 ng/mL in 65% of the subjects. Conclusions: Our findings point to the fact that plasma levels of MPH show a wide range of changes at similar doses, correlate positively with the doses and, as expected, are not affected by using risperidone, sertraline, fluoxetine, and aripiprazole. Therapeutic drug monitoring may help to optimize MPH dose in patients not responding to treatment or in those experiencing serious side effects, but not in routine clinical practice. The presence of intermediate dose formulations such as 45-mg tablets for OROS-MPH may contribute to the optimization. © © 2014 Wolters Kluwer Health, Inc. All rights reserved.en_US
dc.identifier.doi10.1097/FTD.0000000000000149
dc.identifier.endpage352en_US
dc.identifier.issn0163-4356
dc.identifier.issue3en_US
dc.identifier.pmid25384118en_US
dc.identifier.scopus2-s2.0-84929966329en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage347en_US
dc.identifier.urihttps://dx.doi.org/10.1097/FTD.0000000000000149
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8508
dc.identifier.volume37en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherLippincott Williams and Wilkinsen_US
dc.relation.ispartofTherapeutic Drug Monitoringen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY03585
dc.subjectattention deficit hyperactivity disorderen_US
dc.subjectmethylphenidateen_US
dc.subjectOROSen_US
dc.subjectplasma concentrationen_US
dc.subjecttherapeutic drug monitoringen_US
dc.titlePlasma methylphenidate levels in youths with attention deficit hyperactivity disorder treated with OROS formulationen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu